Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
James F Howard, Saskia Bresch, Angela Genge...
https://pubmed.ncbi.nlm.nih.gov/37059508/Actively Recruiting
Led by Miriam Freimer · Updated on 2026-08-28
15
Participants Needed
3
Research Sites
17 weeks
Total Duration
Researchers are studying the use of subcutaneous zilucoplan injections in adults with acetylcholine receptor antibody positive generalized myasthenia gravis gMG who experience severe exacerbations requiring hospitalization. This phase 3b open-label trial aims to assess if zilucoplan can quickly improve severe symptoms such as respiratory or bulbar dysfunction. The study also explores whether this treatment could offer a less invasive alternative to current therapies like plasma exchange or intravenous immunoglobulin IVIG. Participants will receive daily subcutaneous injections of zilucoplan for 12 weeks, with dosing based on body weight. Treatment begins in the hospital and continues after discharge as an outpatient. Before starting zilucoplan, patients will be vaccinated against meningitis and take antibiotics until vaccination is complete. Patients may also choose standard care options such as plasma exchange or IVIG instead of the study treatment. During the approximately 18-week participation, researchers will monitor medical history, physical exams, vital signs, blood tests, and myasthenia gravis assessments including the Quantitative Myasthenia Gravis QMG score and Myasthenia Gravis Activities of Daily Living MG-ADL scale. Quality of life will be evaluated using the MG Quality of Life 15-item Revised MGQoL15r questionnaire. Ongoing review of medications and side effects will occur. The primary outcome focuses on changes in MG-ADL scores from baseline to Week 2, with additional assessments through Week 12.
CONDITIONS
Zilucoplan for Severe gMG Exacerbations
J
Julie Agriesti, MACPR, CCRC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Miriam Freimer
Lead Sponsor
UCB Pharma
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Zilucoplan (daily subcutaneous injection) | Current Standard Treatment (High-Dose Steroids, Plasma Exchange, or IVIG) |
|---|---|---|
| What it is | A complement C5 inhibitor given as a subcutaneous injection, studied for patients experiencing severe gMG exacerbations requiring hospitalization. | Established acute management options include high-dose corticosteroids, plasma exchange (PLEX), and intravenous immunoglobulin (IVIG), often in combination and as recommended by international guidelines. |
| Role in the trial | Evaluated as an add-on or alternative to current guideline-based therapy in adults with severe gMG exacerbation. | Represents the recommended management for acute exacerbations of generalized myasthenia gravis outside a research study. |
| Primary use | Investigated for the rapid management of neuromuscular weakness and breathing problems during severe gMG exacerbation. | Used for quickly controlling worsening myasthenic symptoms and improving strength in patients with acute gMG exacerbations. |
| How it is given or performed | Daily subcutaneous injections, with dose adjusted by patient weight. Each participant receives prefilled syringes. | Corticosteroids are given orally or intravenously; plasma exchange is performed in multiple sessions over several days; IVIG is given by intravenous infusion, typically over 2–5 days. |
| Evidence status | Efficacy and safety for severe gMG exacerbation are still under investigation; no results posted yet for this acute indication. Zilucoplan was previously shown beneficial in sub-acute gMG in a randomized trial. | High-dose corticosteroids, IVIG, and plasma exchange have decades of evidence and are supported by international guidelines as effective treatments for acute gMG emergencies. |
| Important limitations | Data for acute severe exacerbations are limited; ongoing trial with small sample size; prior evidence mostly in stable or less acute gMG settings. | Plasma exchange and IVIG require inpatient care and specialized resources, and some patients may have incomplete or slow response. Steroids may cause side effects and often act with a delayed onset. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive daily subcutaneous injections of zilucoplan for 12 weeks, starting during hospitalization and continuing as outpatients after discharge. Vaccinations and antibiotic use occur as needed.
Regular visits during hospitalization and outpatient follow-ups
Duration - Approximately 6 weeks
Participants continue to be monitored for safety, treatment response, and adverse events for approximately 6 weeks after treatment completion.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
James F Howard, Saskia Bresch, Angela Genge...
https://pubmed.ncbi.nlm.nih.gov/37059508/Aditya Mandawat, Henry J Kaminski, Gary Cutter...
https://pubmed.ncbi.nlm.nih.gov/21061395/Mahima Kapoor, Jennifer Spillane, Christina Englezou...
https://pubmed.ncbi.nlm.nih.gov/31852814/Che-Cheng Chang, Jiann-Horng Yeh, Hou-Chang Chiu...
https://pubmed.ncbi.nlm.nih.gov/38156090/Ema Rodrigues, Emeka Umeh, Aishwarya...
https://pubmed.ncbi.nlm.nih.gov/38040629/Linda L Kusner, Henry J Kaminski
https://pubmed.ncbi.nlm.nih.gov/23252907/Nils E Gilhus
https://pubmed.ncbi.nlm.nih.gov/28029925/Tuan Vu, Andreas Meisel, Renato Mantegazza...
https://pubmed.ncbi.nlm.nih.gov/38319212/Donald B Sanders, Gil I Wolfe, Michael Benatar...
https://pubmed.ncbi.nlm.nih.gov/27358333/Gil I Wolfe, Henry J Kaminski, Inmaculada B Aban...
https://pubmed.ncbi.nlm.nih.gov/27509100/Miriam Freimer
Lead Sponsor
UCB Pharma
Collaborating Sponsor